Blueprint Medicines Corp (NASDAQ: BPMC) kicked off on Monday, up 26.09% from the previous trading day, before settling in for the closing price of $101.35. Over the past 52 weeks, BPMC has traded in a range of $73.04-$121.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 50.22%. While this was happening, its average annual earnings per share was recorded 34.23%. With a float of $62.21 million, this company’s outstanding shares have now reached $64.56 million.
The extent of productivity of a business whose workforce counts for 649 workers is very important to gauge. In terms of profitability, gross margin is 95.84%, operating margin of -31.01%, and the pretax margin is -27.38%.
Blueprint Medicines Corp (BPMC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Blueprint Medicines Corp is 3.68%, while institutional ownership is 106.92%. The most recent insider transaction that took place on May 27 ’25, was worth 505,692. In this transaction Director of this company sold 5,000 shares at a rate of $101.14, taking the stock ownership to the 146,630 shares. Before that another transaction happened on May 27 ’25, when Company’s Director proposed sale 5,000 for $101.14, making the entire transaction worth $505,686.
Blueprint Medicines Corp (BPMC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.23% per share during the next fiscal year.
Blueprint Medicines Corp (NASDAQ: BPMC) Trading Performance Indicators
Take a look at Blueprint Medicines Corp’s (BPMC) current performance indicators. Last quarter, stock had a quick ratio of 2.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach 0.91 in one year’s time.
Technical Analysis of Blueprint Medicines Corp (BPMC)
The latest stats from [Blueprint Medicines Corp, BPMC] show that its last 5-days average volume of 10.15 million was superior to 1.43 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 92.36%. Additionally, its Average True Range was 5.67.
During the past 100 days, Blueprint Medicines Corp’s (BPMC) raw stochastic average was set at 99.35%, which indicates a significant increase from 98.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.93% in the past 14 days, which was higher than the 64.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $92.81, while its 200-day Moving Average is $93.63. Now, the first resistance to watch is $128.15. This is followed by the second major resistance level at $128.51. The third major resistance level sits at $128.87. If the price goes on to break the first support level at $127.43, it is likely to go to the next support level at $127.07. The third support level lies at $126.71 if the price breaches the second support level.
Blueprint Medicines Corp (NASDAQ: BPMC) Key Stats
The company with the Market Capitalisation of 8.25 billion has total of 64,582K Shares Outstanding. Its annual sales at the moment are 508,820 K in contrast with the sum of -67,090 K annual income. Company’s last quarter sales were recorded 149,410 K and last quarter income was 500 K.
